Biocon founder Kiran Mazumdar-Shaw found inspiration in a childhood drawing from her nephew Eric. The artwork depicted a pot of gold coins ...

Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the last six month...

Biocon API business: Biocon has refuted claims of considering the sale of its generic active pharmaceutical ingredient (API) business, valu...

"I am delighted to welcome Peter to the Biocon Group in the role of Group CEO. Siddharth Mittal, CEO & MD Biocon Limited, Shreehas Tambe, C...

Eswara Reddy along with Animesh Kumar (Assistant Drugs Inspector), Biocon Biologics' Associate Vice President L Praveen Kumar, and Synergy ...

To fund the upfront payment, Biocon Biologics has secured $1.2 billion of Sustainability Linked Loan (SLL). The balance has been funded thr...

Those arrested include a Joint Drug Controller (JDC), posted at CDSCO Headquarters, New Delhi, an executive of M/s Biocon Biologics Limited...

A special court here had sent all the five accused, including a joint drug controller at Central Drugs Standard Control Organisation, to ju...

After completing the necessary paperwork, the CBI has arrested Reddy and Dua, nabbed during a trap operation on Monday while the alleged br...

It was alleged that the accused was trying to exert undue influence on officers of CDSCO (Central Drugs Standard Control Organisation) unde...

BC Asia Investments X Ltd is indirectly held by Bain Capital Investors LLC (Bain Private Equity), Bain Capital Credit Member LLC and Bain C...

The Serum alliance would give Biocon Biologics' access to 100 million doses of vaccines per annum for 15 years with commercialisation right...

“2020 has been one of the most challenging years for the world with an unprecedented pandemic impact on the global economy. We continue to ...

As per the terms of the proposed agreement, ADQ will invest Rs 555 Crore for a 1.80 per cent minority stake in the biosimilar business, val...

The stock is trading at 32 times FY22E EPS, which factors in the benefit from potential launches, but not the risks involved.

Eye minority stake in Biocon Biologics; unit may be valued at $4 billion, higher than the market cap of Biocon.

Analysts gave a thumbs up to Biocon after the company said its copy of biopharmaceutical insulin glargine met the primary targets, which in...